Literature DB >> 8938205

Is postictal electrical silence a predictor of response to electroconvulsive therapy?

T Suppes1, A Webb, T Carmody, E Gordon, R Gutierrez-Esteinou, J I Hudson, H G Pope.   

Abstract

Electroconvulsive therapy (ECT) is an established effective treatment modality for patients with severe depression. Recent studies have focused on developing predictors of response. In this prospective study, using percent decrease in Hamilton Depression Scale (21 items) as the outcome measure, we blindly evaluated 33 inpatients with major depression to determine whether postictal suppression, the electrical silence following induced seizure, would predict treatment response to ECT. A significant relationship was observed between degree of postictal suppression and likelihood of clinical improvement. Postictal suppression should be explored in more controlled studies as a predictor of ECT response.

Entities:  

Mesh:

Year:  1996        PMID: 8938205     DOI: 10.1016/0165-0327(96)00066-3

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  10 in total

1.  Management of poor postictal suppression during electroconvulsive therapy with propofol anesthesia: a report of two cases.

Authors:  Jonathan T Stewart
Journal:  J Anesth       Date:  2012-07-24       Impact factor: 2.078

Review 2.  Device-Based Modulation of Neurocircuits as a Therapeutic for Psychiatric Disorders.

Authors:  Zhi-De Deng; Bruce Luber; Nicholas L Balderston; Melbaliz Velez Afanador; Michelle M Noh; Jeena Thomas; William C Altekruse; Shannon L Exley; Shriya Awasthi; Sarah H Lisanby
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-01-06       Impact factor: 13.820

3.  A novel Seizure Quality Index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development.

Authors:  Laura Kranaster; Suna Su Aksay; Jan Malte Bumb; Carolin Hoyer; Christine Jennen-Steinmetz; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-06-06       Impact factor: 5.270

Review 4.  Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management.

Authors:  Mohamed Naguib; Robert Koorn
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  [Electroconvulsive therapy at the Department of Psychiatry and Psychotherapy, University of Munich. Development during the years 1995-2002].

Authors:  T C Baghai; A Marcuse; H-J Möller; R Rupprecht
Journal:  Nervenarzt       Date:  2005-05       Impact factor: 1.214

6.  Does remifentanil improve ECT seizure quality?

Authors:  Verònica Gálvez; Phern-Chern Tor; Adriana Bassa; Dusan Hadzi-Pavlovic; Ross MacPherson; Mincho Marroquin-Harris; Colleen K Loo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-01       Impact factor: 5.270

7.  Are morphological changes necessary to mediate the therapeutic effects of electroconvulsive therapy?

Authors:  Thomas Nickl-Jockschat; Nicola Palomero Gallagher; Vinod Kumar; Felix Hoffstaedter; Elisabeth Brügmann; Ute Habel; Simon B Eickhoff; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-11       Impact factor: 5.270

8.  A Retrospective Study of Postictal Suppression during Electroconvulsive Therapy.

Authors:  Virginie Moulier; Julien Guehl; Emilie Evêque-Mourroux; Pierre Quesada; Maud Rothärmel
Journal:  J Clin Med       Date:  2022-03-05       Impact factor: 4.241

9.  Focal electrically administered seizure therapy: a novel form of ECT illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction.

Authors:  Timothy Spellman; Angel V Peterchev; Sarah H Lisanby
Journal:  Neuropsychopharmacology       Date:  2009-02-18       Impact factor: 7.853

10.  Isoflurane but Not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression?

Authors:  P Leon Brown; Panos Zanos; Leiming Wang; Greg I Elmer; Todd D Gould; Paul D Shepard
Journal:  Int J Neuropsychopharmacol       Date:  2018-08-01       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.